Volume 6.43 | Nov 13

Prostate Cell News 6.43 November 13, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Cytoplasmic PML Promotes TGF-β-Associated Epithelial–Mesenchymal Transition and Invasion in Prostate Cancer
The authors report a previously unknown role for the cytoplasmic promyelocytic leukemia (cPML) tumor suppressor in transforming growth factor (TGF)-β signaling-induced regulation of prostate cancer-associated epithelial–mesenchymal transition and invasion. They demonstrated that cPML promotes a mesenchymal phenotype and increases the invasiveness of prostate cancer cells. [Oncogene] Full Article
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

The Ascidian Natural Product Eusynstyelamide B Is a Novel Topoisomerase II Poison that Induces DNA Damage and Growth Arrest in Prostate and Breast Cancer Cells
The authors investigated the mechanism of action of eusynstyelamide B (EB) in cancer cell lines of the prostate and breast. EB inhibited cell growth and induced a G2 cell cycle arrest, as shown by a significant increase in the G2/M cell population in the absence of elevated levels of the mitotic marker phospho-histone H3. [Oncotarget] Full Article

Inhibition of Pten Deficient Castration Resistant Prostate Cancer by Targeting of the SET – PP2A Signaling Axis
Researchers showed that targeting the endogenous PP2A regulator, SET, is a viable strategy to inhibit prostate cancers that are resistant to androgen deprivation therapy. [Sci Rep] Full Article

Nucleoporin 62 and Ca2+/Calmodulin Dependent Kinase Kinase 2 Regulate Androgen Receptor Activity in Castrate Resistant Prostate Cancer Cells
Ca2+/calmodulin-dependent kinase kinase 2 was previously shown to regulate androgen receptor activity in androgen-responsive prostate cancer cells. The authors explored the basis of this regulation in castrate-resistant prostate cancer cells. [Prostate] Abstract

Inhibiting Inducible miR-223 Further Reduces Viable Cells in Human Cancer Cell Lines MCF-7 and PC3 Treated by Celastrol
Investigators report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects. [BMC Cancer] Full Article

Curcumin Analog WZ35 Induced Cell Death via ROS-Dependent ER Stress and G2/M Cell Cycle Arrest in Human Prostate Cancer Cells
Researchers showed that WZ35 exhibited much higher cell growth inhibition than curcumin by inducing ER stress-dependent cell apoptosis in human prostate cells. The reduction of CHOP expression by siRNA partially abrogated WZ35-induced cell apoptosis. [BMC Cancer] Full Article

Network Analysis of an In Vitro Model of Androgen-Resistance in Prostate Cancer
Researchers developed an in vitro model of androgen-resistance to characterize molecular changes occurring as androgen resistance evolves over time. They aimed to understand biological network profiles of transcriptomic changes occurring during the transition to androgen-resistance and to validate these changes between the in vitro model and clinical datasets. [BMC Cancer] Full Article

Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression
Scientists showed that DNA topoisomerase 2 alpha promotes tumor aggressiveness by inducing chromosomal rearrangements of genes that contribute to a more invasive phenotype. Anti-androgen treatment alone was ineffective in killing TOP2A overexpressing cells due to activation of an androgen receptor network. [PLoS One] Full Article

Kindlin-2 Promotes Invasiveness of Prostate Cancer Cells via NF-κB-Dependent Upregulation of Matrix Metalloproteinases
Researchers investigated the role of kindlin-2, an integrin-binding focal adhesion protein, in the regulation of invasiveness of prostate cancer. [Gene] Abstract


Temsirolimus Maintenance Therapy after Docetaxel Induction in Castration-Resistant Prostate Cancer
The authors designed a single-arm Phase II trial to explore whether the mTOR inhibitor temsirolimus can maintain the response to docetaxel without compromising quality of life. [Oncologist] Abstract

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer
The authors highlight emerging mechanisms of acquired resistance to contemporary castration-resistant prostate cancer therapies, which fall into three broad categories of restored androgen receptor (AR) signaling, AR bypass signaling and complete AR independence. [Nat Rev Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Sophiris Bio Phase III BPH Study Successfully Meets Primary Endpoint
Sophiris Bio Inc. announced final results from its Phase III “PLUS-1” study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia. [Sophiris Bio Inc.] Press Release

Moffitt Cancer Center’s Physical Sciences – Oncology Center Receives $10.4 Million Grant to Study the Intersection of Evolution and Cancer Therapy
The Integrated Mathematical Oncology Department integrates their skills with cancer biologists and oncologists in teams to use mathematical models to better understand cancer progression and treatment. This team driven science has led to pioneering work that has recently been acknowledged through a $10.4 million award from the National Cancer Institute. [Moffitt Cancer Center (Newswise, Inc.)] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW German Cancer Congress 2016
February 24-27, 2016
Berlin, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Researcher – Computational Modeling of Prostate Cancer (IBM, Zurich Research Laboratory)

Postdoctoral Position – Androgen Response in Prostate Cancer (University of Victoria)

Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us